These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 33059737)

  • 1. SETDB1 promotes glioblastoma growth via CSF-1-dependent macrophage recruitment by activating the AKT/mTOR signaling pathway.
    Han S; Zhen W; Guo T; Zou J; Li F
    J Exp Clin Cancer Res; 2020 Oct; 39(1):218. PubMed ID: 33059737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticancer effects of veratramine via the phosphatidylinositol-3-kinase/serine-threonine kinase/mechanistic target of rapamycin and its downstream signaling pathways in human glioblastoma cell lines.
    Kim D; Kwon W; Park S; Kim W; Park JK; Han JE; Cho GJ; Yun S; Han SH; Kim MO; Ryoo ZY; Choi SK
    Life Sci; 2022 Jan; 288():120170. PubMed ID: 34826438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epithelial membrane protein 1 promotes glioblastoma progression through the PI3K/AKT/mTOR signaling pathway.
    Miao L; Jiang Z; Wang J; Yang N; Qi Q; Zhou W; Feng Z; Li W; Zhang Q; Huang B; Chen A; Zhang D; Zhao P; Li X
    Oncol Rep; 2019 Aug; 42(2):605-614. PubMed ID: 31233190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HHLA2 deficiency inhibits pancreatic cancer progression and THP-1 macrophage M2 polarization via EGFR/MAPK/ERK and mTOR/AKT pathway.
    Zhou S; Wang Z; Zhao D; Fu Y; Zhang S; Wang Z; Zou X
    World J Surg Oncol; 2024 May; 22(1):133. PubMed ID: 38762741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MTHFD1L as a folate cycle enzyme correlates with prognostic outcome and its knockdown impairs cell invasive behaviors in osteosarcoma via mediating the AKT/mTOR pathway.
    Wang L; Yang Y; Wang XM; Wang CQ; Zhang YM; Li BL
    J Recept Signal Transduct Res; 2020 Dec; 40(6):584-590. PubMed ID: 32456526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancer of zeste homolog 2 promotes hepatocellular cancer progression and chemoresistance by enhancing protein kinase B activation through microRNA-381-mediated SET domain bifurcated 1.
    Zhou J; Che J; Xu L; Yang W; Li Y; Zhou W; Zou S
    Bioengineered; 2022 Mar; 13(3):5737-5755. PubMed ID: 35184652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TRAF4 Promotes the Proliferation of Glioblastoma by Stabilizing SETDB1 to Activate the AKT Pathway.
    Gu H; Zhu S; Peng C; Wei Z; Shen Y; Yuan C; Yang H; Cui H; Yang L
    Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyrroline-5-Carboxylate Reductase-2 Promotes Colorectal Cancer Progression via Activating PI3K/AKT/mTOR Pathway.
    Yin F; Huang X; Xuan Y
    Dis Markers; 2021; 2021():9950663. PubMed ID: 34512817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. circPARD3 drives malignant progression and chemoresistance of laryngeal squamous cell carcinoma by inhibiting autophagy through the PRKCI-Akt-mTOR pathway.
    Gao W; Guo H; Niu M; Zheng X; Zhang Y; Xue X; Bo Y; Guan X; Li Z; Guo Y; He L; Zhang Y; Li L; Cao J; Wu Y
    Mol Cancer; 2020 Nov; 19(1):166. PubMed ID: 33234130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An miR-340-5p-macrophage feedback loop modulates the progression and tumor microenvironment of glioblastoma multiforme.
    Liu Y; Li X; Zhang Y; Wang H; Rong X; Peng J; He L; Peng Y
    Oncogene; 2019 Dec; 38(49):7399-7415. PubMed ID: 31427735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TRIM59 predicts poor prognosis and promotes pancreatic cancer progression via the PI3K/AKT/mTOR-glycolysis signaling axis.
    Li R; Weng L; Liu B; Zhu L; Zhang X; Tian G; Hu L; Li Q; Jiang S; Shang M
    J Cell Biochem; 2020 Feb; 121(2):1986-1997. PubMed ID: 31693252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CEP55 promotes epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway.
    Chen H; Zhu D; Zheng Z; Cai Y; Chen Z; Xie W
    Clin Transl Oncol; 2019 Jul; 21(7):939-949. PubMed ID: 30607788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cucurbitacin E inhibits esophageal carcinoma cell proliferation, migration, and invasion by suppressing Rac1 expression through PI3K/AKT/mTOR pathway.
    Zhang L; Liang H; Xin Y
    Anticancer Drugs; 2020 Sep; 31(8):847-855. PubMed ID: 32568828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long noncoding RNA-JPX predicts the poor prognosis of ovarian cancer patients and promotes tumor cell proliferation, invasion and migration by the PI3K/Akt/mTOR signaling pathway.
    Li J; Feng L; Tian C; Tang YL; Tang Y; Hu FQ
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8135-8144. PubMed ID: 30556851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone methyltransferase SETDB1 promotes colorectal cancer proliferation through the STAT1-CCND1/CDK6 axis.
    Yu L; Ye F; Li YY; Zhan YZ; Liu Y; Yan HM; Fang Y; Xie YW; Zhang FJ; Chen LH; Ding Y; Chen KL
    Carcinogenesis; 2020 Jul; 41(5):678-688. PubMed ID: 31306481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of HOXC10 promotes glioblastoma cell progression to a poor prognosis via the PI3K/AKT signalling pathway.
    Guan Y; He Y; Lv S; Hou X; Li L; Song J
    J Drug Target; 2019 Jan; 27(1):60-66. PubMed ID: 29768063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RabGEF1 functions as an oncogene in U251 glioblastoma cells and is involved in regulating AKT and Erk pathways.
    Fan H; Xin T; Dong X; Yang F; Zhang R; Feng S; He D; Guo H; Pang Q
    Exp Mol Pathol; 2021 Feb; 118():104571. PubMed ID: 33166495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ARL4C stabilized by AKT/mTOR pathway promotes the invasion of PTEN-deficient primary human glioblastoma.
    Chen Q; Weng HY; Tang XP; Lin Y; Yuan Y; Li Q; Tang Z; Wu HB; Yang S; Li Y; Zhao XL; Fu WJ; Niu Q; Feng H; Zhang X; Wang Y; Bian XW; Yao XH
    J Pathol; 2019 Feb; 247(2):266-278. PubMed ID: 30357833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A molecular cascade modulates MAP1B and confers resistance to mTOR inhibition in human glioblastoma.
    Laks DR; Oses-Prieto JA; Alvarado AG; Nakashima J; Chand S; Azzam DB; Gholkar AA; Sperry J; Ludwig K; Condro MC; Nazarian S; Cardenas A; Shih MYS; Damoiseaux R; France B; Orozco N; Visnyei K; Crisman TJ; Gao F; Torres JZ; Coppola G; Burlingame AL; Kornblum HI
    Neuro Oncol; 2018 May; 20(6):764-775. PubMed ID: 29136244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistance.
    Liu Z; Liu J; Ebrahimi B; Pratap UP; He Y; Altwegg KA; Tang W; Li X; Lai Z; Chen Y; Shen L; Sareddy GR; Viswanadhapalli S; Tekmal RR; Rao MK; Vadlamudi RK
    Breast Cancer Res; 2022 Apr; 24(1):26. PubMed ID: 35395812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.